Inherited bleeding disorders: Disorders of platelet adhesion and aggregation

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 1, 2004, Pages 1-35

  Ramasamy, Indra ^a  

^a NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Inherited disorders of platelet function

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; NITRIC OXIDE; PROSTAGLANDIN; PROTHROMBIN; THROMBIN; THROMBOXANE A2;

BERNARD SOULIER DISEASE; BLEEDING DISORDER; CHEDIAK HIGASHI SYNDROME; ENZYME DEFICIENCY; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; MOLECULAR BIOLOGY; OCULAR ALBINISM; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VASCULAR ENDOTHELIUM; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME;

EID: 0346639224     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00117-3     Document Type: Review

References (397)

1. Blockmans D., Deckmyn H., Vermlyn J. Platelet activation. Blood Rev. 9:1995;143-156.
2. Fox J.E.B., Meyer S.C. Berndt M.C. The platelet cytoskeleton in platelets, thrombosis and the vessel wall. 2000;Harwood Academic Publishers.
3. Ginsberg M.H., Xiaoping D., O'Toole T.E., Loftus J.C., Plow E.F. Platelet integrins. Thromb. Haemost. 87:1993;87-93.
4. George J.N. Platelets. Lancet. 355:2000;153-1543.
5. Ginsburg D., Handin R.I., Bonthron D.T., et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localisation. Science. 228:1985;1401.
6. Mayadas T.N., Wagner D.D. Vicinal cysteines in the prosequence play a role in von Willebrand Factor multimer assembly. Proc. Natl. Acad. Sci. 89:1992;3531-3535.
7. Verweij C.L., Hart M., Pannekoek H. Expression of variant von Willebrand factor (vWF) in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J. 6:1987;2885-2890.
8. Wise R.J., Dorner A.J., Krane M., Pittman D.D., Kaufman R.J. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilisation of factor VIII. J. Biol. Chem. 266:1991;21948-21955.
9. Wagner D.D., Lawrence S.O., Ohlsson-Wihelm B.M., Fay P.J., Marder V.J. Topology and order of formation of interchain disulphide bonds in von Willebrand factor. Blood. 69:1987;27-32.
10. Marti T., Rosselet S.J., Titani K., Walsh K.A. Identification of disulphide-bridged substructures within von Willebrand factor. Biochemistry. 26:1987;8099-8109.
11. Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the vWF propeptide and mature subunit that enable vWF storage. Blood online 2002. 200207228.
12. Rosenberg J.B., Foster P.A., Kaufman R.J., et al. Intracellular trafficking of Factor VIII to von willebrand factor storage granules. J. Clin. Invest. 101:1998;613-624.
13. Xie L., Chesterman C.N., Hogg P.J. Control of von Willebrand factor multimer size by thrombospondin-1. J. Exp. Med. 193:2001;1341-1350.
14. Ruggeri Z.M. Structure and function of von Willebrand factor. Thromb. Haemost. 82:1999;576-584.
15. Howard M.A., Firkin B.G. Ristocetin - a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh. 26:1971;362-369.
16. Read M.S., Smith S.V., Lamb M.A., Brinkhous K.M. Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood. 74:1989;1031-1035.
17. Siediecki C.A., Lestini B.J., Kottke-Marchant K.K., et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 88:1996;2939-2950.
18. Santoro S.A. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb. Res. 21:1981;689-691.
19. Morton L.F., Griffin B., Pepper D.S., Barnes M.J. The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction. Thromb. Res. 32:1983;545-556.
20. Rand J.H., Patel N.D., Schwartz E., Zhou S.L., Potter B.J. 150 kDa von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. J. Clin. Invest. 88:1991;243-259.
21. Berlanga O., Tulasne D., Bori T., et al. The Fc receptor γ-chain is necessary and sufficient to initiate signalling through glycoprotein VI in transfected cells by the snake C-type lectin, convulxin. Eur. J. Biochem. 269:2002;2951-2960.
22. Watson S.P. Collagen receptor signalling in platelets and megakaryocytes. Thromb. Haemost. 82:1999;365-376.
23. Quinton T.M., Ozdner F., Dangelmaier C., Daniel J.L., Kunapuli S.P. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood. 99:2002;3228-3234.
24. Atkinson B.T., Stafford M.J., Peras C.J., Watson S.P. Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur. J. Biochem. 268:2001;5242-5248.
25. Rand J.H., Wu X.X., Potter B.J., Uson R.R., Gordon R.E. Co-localisation of von Willebrand factor and type VI collagen in human vascular endothelium. Am. J. Pathol. 142:1993;843-850.
26. Ross J.M., McIntire L.V., Moake J.L., Rand J.H. Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood. 85:1995;1826-1835.
27. Kessler C.M., Floyd C.M., Rick M.E., Krizek D.M., Lee S.L., Gralnick H.R. Collage-factor VIII/von Willebrand factor protein interaction. Blood. 63:1984;1291-1298.
28. Bockenstadt P., Greenberg J.M., Handin R.I. Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. J. Clin. Invest. 77:1986;743-749.
29. Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67:1998;395-424.
30. Lankhof H., van Hoeij M., Schiphorst M.E., et al. A3 domain is essential for interaction of von Willebrand Factor with collagen type III. Thromb. Haemost. 75:1996;950-958.
31. Mazzucato M., Spessotto P., Masotti A., et al. Identification of domains responsible for von Willebrand Factor type VI collagen interaction. J. Biol. Chem. 274:1999;3033-3041.
32. Wu D., Vanhoorelbeke K., Cauwenberghs N., et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial thrombus formation in baboons. Blood. 99:2002;3623-3628.
33. Bienkowska J., Cruz M., Atiemo A., Handin R., Liddington R. The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J. Biol. Chem. 272:1997;25162-25167.
34. Huizinga E.G., van der Plas R.M., Kroon J., Sixma J.J., Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure. 5:1997;1147-1156.
35. Mohri H., Yoshioka A., Zimmerman T.S., Ruggeri Z.M. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin and collagen, characterisation of its three functional sites. J. Biol. Chem. 264:1989;17361-17367.
36. Sugimoto M., Ricca G., Hrindda M.E., et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry. 30:1991;5202-5209.
37. Berndt M.C., Ward C.M., Booth W.J., et al. Identifcation of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand Factor by ristocetin and botrocetin. Biochemistry. 31:1992;1114-11151.
38. Kroner P.A., Frey A.B. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine scanning mutagenesis. Biochemistry. 35:1996;13460-13468.
39. Matsushita T., Sadler T.E. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged to alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J. Biol. Chem. 270:1995;13406-13414.
40. Emsley J., Cruz M., Handin R., Liddington R. Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein 1b. J. Biol. Chem. 273:1998;10396-10401.
41. Celikel R., Varughese K.I., Madhusudan K.I., Yoshioka A., ware J., Ruggeri Z.M. Crystal structure of von Willebrand factor A1 domain in complex with the function of blocking NMC-4 Fab. Nat. Struct. Biol. 5:1998;189-194.
42. Cruz M.A., Diacovo T.G., Emsley J., Liddington R., Handin R.I. Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain. J. Biol. Chem. 275:2000;19098-19105.
43. Vasudevan S., Roberts J.R., McClintock R.A., et al. Modelling and functional analysis of the interaction between von Willebrand Factor A1 domain and glycoprotein 1bα J. Biol. Chem. 275:2000;12763-12768.
44. Matsushita T., Meyer D., Sadler J.E. Localisation of von Willebrand Factor-binding sites for glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J. Biol. Chem. 275:2000;11044-11049.
45. Girma J.P., Takahashi Y., Yoshioka A., diaz J., Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb. Haemost. 64:1990;326-332.
46. Ruggeri Z.M. Von Willebrand factor. J. Clin. Invest. 99:1997;559-564.
47. Foster P.A., Fulcher C.A., Marti T., Titani K., Zimmerman T.S. A major factor VIII binding residues within the amino terminal 272 amino acid residues of von Willebrand factor. J. Biol. Chem. 262:1987;8443-8446.
48. Pietu G., Ribba A.S., Cherel G. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb. Haemost. 71:1994;788-792.
49. Jorieux S., Gaucher C., Pietu G., Cherel G., Meyer D., Mazurier C. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain. Br. J. Haematol. 87:1994;113-118.
50. Bahou W.F., Ginsburg D., Sikkink R., Litwiller R., Fass D.N. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding: localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J. Clin. Invest. 84:1989;56-61.
51. Li C.Q., Dong J., Lanza F., Sanan D.A., Sae-Ting G., Lopez J.A. Expression of platelet glycoprotein (GP) V in heterologous cells and evidence for its association with GP Ibα in forming a GP Ib-IX-V complex on the cell surface. J. Biol. Chem. 270:1995;16302-16307.
52. Lopez J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul. Fibrinol. 5:1994;97-119.
53. Andrews R.K., Shen Y., Gardiner E.E., Dong J., Lopex J.A., Berndt M.C. The glycoprotein Ib-IX-V complex in platelet adhesion and signalling. Thromb. Haemost. 82:1999;357-364.
54. Andrews R.K., Lopez J.A., Berndt M.C. Molecular mechanisms of platelet adhesion and activation. Int. J. Biochem. Cell. Biol. 29:1997;91-105.
55. Kahn M.L., Diacovo T.G., Bainton D.F., Lanza F., Trejo J., Coughlin S.R. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood. 94:1999;4112-4121.
56. Lopez J.A., Weisman S., Sanan D.A., Sih T., Chambers M., Li C.Q. Glycoprotein (GP) Ib beta is the critical subunit linking GP Ib alpha and GP IX in the GP Ib-IX complex. Analysis of partial complexes. J. Biol. Chem. 269:1994;23716-23721.
57. Huizinga E.G., Tsuji S., Romijn R.A.P., et al. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science. 297:2002;1176-1177.
58. Nieuwenhuis H.K., Akkerman J.W.N., Houdijk W.P.M., Sixma J.J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 318:1985;470-472.
59. Nieuwenhius H.K., Sakariassen K.S., Houdijik W.P.M., Nievelstein P.F.E.M., Sixma J.J. Deficiency of platelet membrane glycoprotein Ia associated with decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood. 68:1986;692-695.
60. Saelman E.U., Niewenhuis H.K., Hese K.M., et al. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GP Ia/IIa (alpha 2 beta 1-integrin). Blood. 83:1994;1244-1290.
61. Springer T.A. Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc. Natl. Acad. Sci. 94:1997;65-72.
62. 1. J. Biol. Chem. 272:1997;28512-28517.
63. 1. Cell. 100:2000;47-56.
64. 1. J. Biol. Chem. 275:2000;8016-8026.
65. Pintigny D., Legrand C., Karniguaian A., Legrand Y.J., Caen J.P. Evidence that a collagen derived octapeptide inhibits fibrinogen binding to platelets stimulated by collagen and not by ADP. Biochem. Biophys. Res. Commun. 128:1985;547-553.
66. Kotite N.J., Staros J.V., Cunningham L.W. Interaction of specific platelet membrane proteins with collagen: evidence from chemical cross-linking. Biochemistry. 23:1984;3099-3104.
67. Sugiyama T., Okuma M., Ushikubi F., Senaki S., Kanaji K., Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood. 69:1987;1712-1720.
68. Clemetson J.M., Polgar J., Magnenat E., Wells T.N.C., Clemetson K.J. The platelet collagen receptor Glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcαR and the natural killer receptors. J. Biol. Chem. 274:1999;29019-29024.
69. Jandrot-Perrus M., Busfield S., Lagrue A.H., et al. Cloning characterisation and functional studies of human and mouse glycoprotein VI: a platelet specific collagen receptor from the immunoglobulin superfamily. Blood. 96:2000;1798-1807.
70. Morton L.F., Hargreaves P.G., Farndale R.W., Young R.D., Barnes M.J. Integrin alpha2beta1-independent activation of platelets by simple collagen-like peptides: collagen tertiary triple-helical and quaternary (polymeric) structures are sufficient alone for alpha2beta1-independent platelet reactivity. Biochem. J. 306:1995;337-344.
71. Asselin J., Gibbins J.M., Achison M., et al. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C gamma 2 in platelets independent of the integrin alpha2beta1. Blood. 89:1997;1235-1242.
72. Kehrel B., Wierwille S., Clemetson K.J., et al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand Factor do not. Blood. 91:1998;491-499.
73. Polgar J., Clemetson J.M., Kehrel B.E., et al. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J. Biol. Chem. 273:1997;13576-13583.
74. Niedergang F., Alcover A., Knight C.G., et al. Convulxin binding to platelet receptor GPVI: competition with collagen related peptides. Biochem. Biophys. Res. Commun. 273:2000;246-250.
75. Morton L.F., Peachey A.R., Barnes M.J. Platelet reactive sites in collagen type I and type III. Evidence for separate adhesion and aggreagtory sites. Biochem. J. 258:1989;157-163.
76. Huang T.F., Liu C.Z., Yang S.H. Aggretin, a novel platelet aggregation inducer from snake (Calloselasma rhodostoma) venom activates phospholipase C by acting as a glycoprotein Ia/IIa agonist. Biochem. J. 309:1995;102'1-1027.
77. Teng C.M., Ko F.N., Tsai I.H., Hung M.L., Hung T.F. Trimucytin: a collagen-like aggregating inducer isolated from Trimeresurus mucrosquamatus snake venom. Thromb. Haemost. 69:1993;286-292.
78. 1. J. Biol. Chem. 272:1997;27035-27041.
79. Rudd C.E., Janssen O., Cai Y.C., Silva A.J., Raab M., Prasad K.V. Two-step TCRz/CD3-CD4 and CD28 signalling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol. Today. 15:1994;225-234.
80. Ichinohe T., Tamarama H., Esimil Y., et al. Collagen stimulated activation of Syk but not c-Src is severely compromised human platelets lacking membrane glycoprotein VI. J. Biol. Chem. 272:1997;63-68.
81. 1 integrin is a necessary co-receptor for collagen-induced activation of Sky and the subsequent phosphorylation of phospholipase Cγ2 in platelets. J. Biol. Chem. 271:1996;2668-2676.
82. 1 in collagen-induced tyrosine phosphorylation in human platelets. Eur. J. Biochem. 267:2000;2088-2097.
83. Daniel J.L., Dangelmaier C., Streusel R., Smith J.B. Collagen induces normal signal transduction in platelets deficient in CD36 (platelet glycoprotein IV). Thromb. Haemost. 71:1994;353-356.
84. Saelman E.U., Kehrel B., Hese K.M., de Groot P.G., Sixma J.J., Nieuwenhuis H.K. Platelet adhesion to collagen and endothelial cell matrix under flow conditions is not dependent on platelet glycoprotein IV. Blood. 83:1994;3240-3244.
85. Chiang T.M., Kang A.H. A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type I collagen mediated platelet aggregation. J. Clin. Invest. 100:1997;2079-2084.
86. Chiang T.M., Rinaldy A., Kang A.H. Cloning, characterisation and functional studies of a nonintegrin platelet receptor for type I collagen. J. Clin. Invest. 100:1997;514-521.
87. Monnet E., Fauvel-Lafeve F. A new platelet receptor specific to type III collagen. J. Biol. Chem. 275:2000;10912-10917.
88. Alevriadou B.R., McIntire L.V. Rheology. Loscalzo J., Schafer A.I. Thrombosis and haemorrhage. 1995;369-384 Blackwell Science Inc.
89. Kroll M.H., Hellums D.J., McIntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood. 88:1996;1525-1541.
90. Frederickson B.J., Dong J.F., McIntire L.V., Lopez J.A. Shear dependent rolling on von Willebrand Factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood. 92:1998;3684-3693.
91. Goto S., Salomon D.R., Ikeda Y., Ruggeri Z.M. Characterisation of the unique mechanism mediating the shear dependent binding of soluble von Willebrand factor to platelets. J. Biol. Chem. 270:1995;23352-23361.
92. Goto S., Ikeda Y., Murata M., et al. Epinephrine augments von Willebrand factor dependent shear induced platelet aggregation. Circulation. 86:1992;1859-1863.
93. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood. 71:1988;1366-1374.
94. Moroi M., Jung S.M., Nomura S., Sekiguchi S., Ordinas A., Diaz-Ricart M. Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood. 90:1997;4413-4424.
95. Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 94:1998;657-676.
96. Verkleij M.W., Morton L.F., Knight C.G., de Groot P.G., Barnes M.J., Sixma J.J. Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2beta1 and von Willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. Blood. 91:1998;3808-3816.
97. Moroi M., Jung S.M., Shinmyozu K., Tomiyama Y., Ordinas A., Diaz-Ricart M. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of Glycoprotein VI in the platelet adhesion. Blood. 88:1996;2081-2092.
98. Coller B.S., Beer J.H., Scudder L.E., Steinberg M.H. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GP Ia-IIa and an indirect interaction with platelet GP IIb-IIIa mediated by adhesive proteins. Blood. 74:1989;182-192.
99. Yuan Y., Kulkarni S., Ulsemer P., et al. The von Willebrand Factor-Glycoprotein Ib/V/IX interaction induces actin polymerisation and cytoskeletal reorganisation in rolling platelets and glycoprotein Ib/V/IX transfected cells. J. Biol. Chem. 274:1999;36241-36251.
100. Mistry N., Cranmer S.L., Yuan Y., et al. Cytoskeletal regulation of the platelet glycoprotein Ib/V/IX-von Willebrand factor interaction. Blood. 96:2000;3480-3489.
101. Barnes M.J., Knight C.G., Farndale R.W. The collagen-platelet interaction. Curr. Opin. Haematol. 5:1998;314-320.
102. Watson S., Berlanga O., Best D., Frampton J. Update on collagen receptor interactions in platelets: is the two-state model still valid. Platelets. 11:2000;252-258.
103. 3 and platelet function. Thromb. Haemost. 78:1997;96-100.
104. Wagner C.L., Mascelli M.A., Neblock D.S., Weisman H.F., Colle B.S., Jordan R.E. Analysis of GP IIb-IIIa receptor number by quantitation of 7E3 binding to human platelets. Blood. 88:1996;907-914.
105. Bray P.F., Rosa J.P., Lingapa V.R., Kan Y.W., McEver R.P., Shuman M.A. Biogenesis of the platelet receptor for fibrinogen: evidence for separate precursors for glycoproteins IIb and IIIa. Proc. Natl. Acad. Sci. 83:1986;1480-1484.
106. Duperray A., Troesch A., Berthier R. Biosynthesis and assembly of platelet GP IIb-IIIa in human megakaryocytes: evidence that assembly between pro-GIIb and GP IIIa is a prerequisite for expression of the complex on the cell surface. Blood. 74:1989;1603-1611.
107. Savage B., Saldivar E., Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand Factor. Cell. 84:1996;289-297.
108. Zamarron C., Ginsberg M.H., Plow E.F. A receptor induced binding site in fibrinogen elicited by its interaction with platelet membrane protein glycoprotein IIb-IIIa. J. Biol. Chem. 266:1991;9550-9557.
109. Farrell D.H., Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J. Biol. Chem. 269:1994;226-231.
110. 3 with multiple fibrinogen domains during platelet adhesion. J. Biol. Chem. 270:1995;28812-28817.
111. Savage B., Shattil S.J., Ruggeri Z.M. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J. Biol. Chem. 267:1992;11300-11306.
112. 3 activation both in platelets and a transfected Chinese hamster ovary cell system. J. Biol. Chem. 275:2000;16779-16787.
113. 3: studies in human platelets and transfected Chinese hamster ovary cells. J. Biol. Chem. 275:2000;41377-41388.
114. 1 integrin and GP VI. J. Biol. Chem. 274:1999;11897-11903.
115. Nachman R.L., Leung L.L.K. Complex formation of platelet membrane glycoprotein IIb and IIIa with fibrinogen. J. Clin. Invest. 69:1982;263-269.
116. Alevriadou B.R., Moake J.L., Turner N.A., et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 81:1993;1263-1276.
117. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L.H., Hellums J.D. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J. Clin. Invest. 78:1986;1456-1461.
118. Shattil S.J., Kashiwagi H., Pampori N. Integrin signalling: the platelet paradigm. Blood. 91:1998;2645-2657.
119. Ikeda Y., Handa M., Kawano K., et al. The role of von Willebrand Factor and fibrinogen in platelet aggregation under varying shear stress. J. Clin. Invest. 87:1991;1234-1240.
120. 3 for fibrinogen. J. Biol. Chem. 274:1999;25301-25307.
121. 3: inside out, outside in and sideways. Thromb. Haemost. 82:1999;318-325.
122. Goto S., Ikeda Y., Saldivar E., Ruggeri Z.M. Distinct mechanisms of platelet aggregation as a consequence of different flow conditions. J. Clin. Invest. 101:1998;479-486.
123. Kulkarni S., Dopheide S.M., Yap C.L., et al. A revised model for platelet aggregation. J. Clin. Invest. 105:2000;783-791.
124. Ruggeri Z.M., Dent J.A., Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 94:1999;172-178.
125. Ruggeri Z.M. Old concepts and new developments in the study of platelet aggregation. J. Clin. Invest. 105:2000;699-701.
126. Roth G.J., Calverley A. Aspirin, platelets, and thrombosis: theory and practice. Blood. 83:1994;885-898.
127. Armstrong R.A. Platelet prostanoid receptors. Pharmacol. Ther. 72:1996;171-191.
128. Hirata T., Ushikibi F., Kakizuka A., Okuma M., Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. J. Clin. Invest. 97:1996;949-956.
129. Habib A., Fitzgerald G.A., Maclouf J. Phosphorylation of the thromboxane receptor α, the predominant isoform expressed in human platelets. J. Biol. Chem. 274:1999;2645-2651.
130. 2-induced platelet aggregation. J. Biol. Chem. 274:1999;29108-29114.
131. Halushka P.V., Mais D.E., Mayeux P.R., Morinelli T.A. Thromboxane, prostaglandin and leukotriene receptors. Annu. Rev. Pharmacol. Toxicol. 10:1989;213-239.
132. Gachet C., Hechler B., Leon C., et al. Activation of ADP receptors and platelet function. Thromb. Haemost. 77:1997;271-275.
133. Mills D.C.B. ADP receptors on platelets. Thromb. Haemost. 76:1996;835-856.
134. Mustard J.F., Perry D.W., Kinlough-Rathbone R.L., Packham M.A. Factors responsible for ADP-induced release reaction of human platelets. Am. J. Physiol. 228:1975;1757-1765.
135. 2 formation on close contact of human platelets in media with low concentration of ionised calcium. Blood. 70:1987;647-651.
136. Jantzen H., Gousset L., Bhaskar V., et al. Evidence for two distinct G-protein coupled ADP receptors mediating platelet activation. Thromb. Haemost. 81:1999;111-117.
137. Jin J., Kunapuli S.P. Co-activation of two different G protein coupled receptors is essential for ADP induced platelet aggregation. Proc. Natl. Acad. Sci. 95:1998;8070-8074.
138. Hechler B., Leon C., Vial C., et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate induced platelet aggregation. Blood. 92:1998;152-159.
139. Daniel J.L., Dangelmaier C., Jin J., Ashby B., Smith J.B., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273:1998;2024-2029.
140. 2T purinoceptors in human platelets. J. Biol. Chem. 271:1996;2879-2881.
141. Jin J., Daniel J.L., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273:1998;2030-2034.
142. Hollopeter G., Jantzen H.M., Vincent D., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 409:2001;202-207.
143. Zhang F.L., Luo L., Gustafson E., et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J. Biol. Chem. 276:2001;8608-8615.
144. Foster C.J., Prosser D.M., Agans J.M., et al. Molecular identification and characterisation of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J. Clin. Invest. 107:2001;1591-1598.
145. Woulfe D., Yang J., Brass L. ADP and platelets: the end of the beginning. J. Clin. Invest. 107:2001;1503-1505.
146. Brass L.F. More pieces of the platelet activation puzzle slide into place. J. Clin. Invest. 104:1999;1663-1665.
147. Kunapuli S.P. P2 receptors and platelet activation. Scientific World J. 2:2002;424-433.
148. Offermanns S., Toombs C.F., Hu Y.H., Simon M.I. Defective platelet aggregation in Gαq mice-deficient mice. Nature. 389:1997;183-186.
149. Leon C., Hechler B., Freund M., et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor null mice. J. Clin. Invest. 104:1999;1731-1737.
150. Ohlmann P., Eckly A., Freund M., Cazenave J.P., Offermanns S., Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen induced aggregation in the absence of Gαq. Blood. 96:2000;2134-2139.
151. Sage S.O., Yamoah E.H., Heemserk J.W. The roles of P(2X1) and P(2T AC) receptors in ADP-evoked calcium signalling in human platelets. Cell Calcium. 28:2000;119-126.
152. Rolf M.G., Brerley C.A., Mahaut-Smith M.P. Platelet shape change evoked by selective activation of P2X1 purinoreceptors with alpha, beta-methylene ATP. Thromb. Haemost. 85:2001;303-308.
153. Oury C., Toth-Zsaboki E., van Geet C., et al. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue. J. Biol. Chem. 275:2000;22611-22614.
154. Mahaut-Smith M.P., Ennion S.J., Rolf M.G., Evans R.J. ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol. 131:2000;108-114.
155. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J. Clin. Invest. 99:1997;1351-1360.
156. Macfarlane S.R., Seatter M.J., Kanke T., Hunter G.D., Plevin R. Proteinase-activated receptors. Pharamcol. Rev. 53:2001;245-282.
157. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. PAR1 and PAR4 mediate activation of human platelets by thrombin. J. Biol. Chem. 103:1999;879-887.
158. Vu T.-K.H., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1991;1057-1068.
159. Chen J., Ishii M., Wang L., Ishii K., Coughlin S.R. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J. Biol. Chem. 269:1994;16041-16045.
160. Vu T.-K.H., Wheaton V.I., Hung D.T., Coughlin S.R. Domains specifying thrombin-receptor interaction. Nature. 353:1991;674-677.
161. Mathews I.I., Padmanabhan K.P., Ganesh V., et al. Cystallographic structures of thrombin complexed with thrombin receptor peptides: existence of novel binding modes. Biochemistry. 33:1994;3266-3279.
162. Coughlin S.R. Protease-activated receptors and platelet function. Thromb. Haemost. 82:1999;353-356.
163. Hein L., Ishii K., Coughlin S.R., Kobilka B.K. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitisation of a G protein-coupled receptor. J. Biol. Chem. 269:1994;27719-27726.
164. Shapiro M.J., Trejo J., Zeng D.W., Coughlin S.R. Role of thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist triggered versus tonic internalisation and intracellular localisation. J. Biol. Chem. 271:1996;32874-32880.
165. Woolkalis M.J., DeMelfi T.J., Blanchard N., Hoxie J.A., Brass L.F. Regulation of thrombin receptors on human umbilical vein endothelial cells. J. Biol. Chem. 270:1995;9868-9875.
166. Li C.Q., Vindigni A., Sadler J.E., Wardell M.R. Platelet glycoprotein Ibα binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin. J. Biol. Chem. 276:2001;6161-6168.
167. Berndt M.C., Phillips D.R. Interaction of thrombin with platelets; purification of the thrombin substrate. Ann. New York Acad. 370:1981;87-95.
168. Ramakrishnan V., DeGuzman F., Bao M., Hall S.W., Leung L.L., Phillips D.R. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc. Natl. Acad. Sci. 98:2001;1823-1828.
169. Goodwin C.A., Wheeler-Jones C.P.D., Kakkar V.V. Thrombin receptor activating peptide does not stimulate platelet procoagulant activity. Biochem. Biophys. Res. Commun. 202:1994;321-327.
170. Dormann D., Clemetson K.J., Kehrel B.E. The GP Ib thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 96:2000;2469-2478.
171. Dicker I.B., Pedicord D.L., Seiffer D.A., Greco N.J. Both the high affinity thrombin receptor (GP Ib-IX-V) and GP IIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity. Thromb. Haemost. 86:2001;1065-1069.
172. Hattori R., Hamilton K.K., Fugate R.D., McEver R.P., Sims P.J. Stimulated secretion of endothelial von Willebrand Factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J. Biol. Chem. 264:1989;7768-7771.
173. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594.
174. Malik A.B., Lo S.K., Bizios R. Thrombin-induced alterations in endothelial permeability. Ann. New York Acad. Sci. 485:1986;293-309.
175. Rabiet M.J., Plantier J.L., rival Y., Genoux Y., Lampugnani M., Dejana E. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler. Thromb. Vasc. Biol. 16:1996;488-496.
176. McNamara C.A., Sarembock I.J., Gimple L.W., Fenton J.W.D., Coughlin S.R., Owens G.K. Thrombin stimulates proliferation of cultured aortic smooth muscle cells by a proteolytically activated receptor. J. Clin. Invest. 91:1993;94-98.
177. Tsopanoglou N.E., Pipilisynetos E., Maragougoudokis M.E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am. J. Physiol. 264:1993;C1302-1307.
178. Coughlin S.R. Thrombin signalling and protease activated receptors. Nature. 407:2000;258-264.
179. Haslam R.J., Dickinson N.T., Jang E.K. Cyclic nucleotides and phosphodiesterases in platelets. Thromb. Haemost. 82:1999;412-423.
180. Dickinson N.T., Jang E.K., Haslam R.J. Activation of cGMP-stimulated phosphodiesterase by nitoprusside limits cAMP accumulation in human platelets. Biochem. J. 323:1997;371-377.
181. Massberg S., Sausbier M., Klatt P., et al. Increased adhesion and aggregation of platelets lacking guanosine 3′,5′ monophosphate kinase I. J. Exp. Med. 189:1999;1255-1263.
182. Tang K.M., Sherwwod J.L., Haslam R.J. Photo affinity labelling of cyclic GMP binding proteins in human platelets. Biochem. J. 294:1993;329-333.
183. Kalafatis M, Egan JO, van't Veer C, Cawthern KM, Mann KG. The regulation of clotting factors. Critical Reviews™ in eukaryotic gene expression. 1997;7:241-80.
184. McVey J.H. Tissue factor pathway. Balliere's Clin. Haematol. 7:1994;469-484.
185. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82:1999;165-174.
186. Ramasamy I. Laboratory investigation of inherited risk factors for venous thrombosis. Clin. Biochem. Rev. 22:2001;6-35.
187. Collen D. The plasminogen (fibrinolytic) system. Thromb. Haemost. 82:1999;259-270.
188. Gao S.W., Morser J., McLean K., Shuman M.A. Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Thromb. Res. 58:1990;421-423.
189. Kruithof E.K.O., Tran-thang D., Bachmann F. Studies on the release of plasminogen activator inhibitor by human platelets. Thromb. Haemost. 55:1986;201-205.
190. 2-antiplasmin is isolated in the platelet α granules. Thromb. Res. 31:1983;387-390.
191. Adelman B., Michelson A.D., Loscalzo J., Greenberg J., Handlin R.I. Plasmin effect on glycoprotein Ib-von Willebrand factor interactions. Blood. 65:1985;32-40.
192. Bithell T.C. Bloom A., et al. The diagnostic approach to the bleeding disorders. Thrombosis and haemostasis. 1993.
193. Peyvandi F., Mannucci P.M. Rare coagulation disorders. Thromb. Haemost. 82:1999;1207-1214.
194. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 69:1987;454-459.
195. Miller C.H., Lenzi R., Breen C. Prevalence of von Willebrand's disease among US adults. Blood. 79:(Suppl 1):1987;377a.
196. Werner E.J., Broxson E.H., Tucker E.L., Giroux D.S., Shults J., Abshire T.C. Prevalence of von Willebrand disease in children: a multiethnic study. J. Paediatr. 123:1993;893-898.
197. Castaman G., Eikenboom J.C., Bertina R.M., Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb. Haemost. 82:1999;1065-1070.
198. Shinmyozu K., Okadome T., Maruyama I., Osame M., Tara M. A study on the frequency of von Willebrand factor deficiency state. Jpn. J. Clin. Haematol. 32:1991;67-68.
199. Cabrera M.E., Artigas C.G., Paez E., et al. von Willebrand disease in the IX region of Chile. Revista Medica de Chile. 117:1989;423-430.
200. Sadler J.E., Mannucci P.M., Berntorp E., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb. Haemost. 84:2000;160-174.
201. Schneppenheim R., Budde U., Ruggeri Z.M. A molecular approach to the classification of von Willebrand disease. Best Practice Res. Haematol. 14:2001;281-298.
202. Lak M., Peyvandi F., Mannucci P.M. Prevalence of bleeding manifestations, hepatitis and alloantibodies to von Willebrand factor in 348 Iranian patients with type 3 von Willebrand disease. Br. J. Haematol. 111:2000;1236-1239.
203. Holmberg L., Nilsson I.M. Genetic variants of von Willebrand's disease. Br. Med. J. 3:1972;317-320.
204. Weiss H.J., Pietu G., Rabinowitz R., Girma J.P., Rogers J., Meyer D. Heterogenous abnormalities in the multimeric structure, antigenic properties, and plasma platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant type IIA von Willebrand's disease. J. Lab. Clin. Med. 101:1983;411-425.
205. Eikenboom J.C., Matsushita T., Reitsma P.H., et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 88:1996;2433-2441.
206. Bodo I., Katsumi A., Tuley E.A. Mutations causing dominant type 1 von Willebrand disease with high penetrance. Blood. 94:(suppl 1):1999;373a.
207. Bodo I., Katsumi A., Tuley E.A., Eikenboom J.C.J., Dong Z., Sadler J.E. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood. 98:2001;2973-2979.
208. Keeney S., Cumming A., Hay C.R.M. Mutations in von Willebrand Factor multimerisation domains are not a common cause of classical type 1 von Willebrand disease. Thromb. Haemost. 82:1999;1446-1450.
209. Mohlke K.L., Purkayastha A.A., Westrick R.J., et al. MvVWF, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyl transferase. Cell. 96:1999;111-120.
210. Ginsburg D. Molecular genetics of von Willebrand Disease. Thromb. Haemost. 82:1999;585-591.
211. Sodetz J.M., Paulson J.C., McKee P.A. Carbohydrate composition and identification of blood group A, B and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J. Biol. Chem. 254:1979;10754-10760.
212. Keightley A.M., Lam Y.M., Brady J.N., Cameron C.L., Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 93:1999;4277-4283.
213. Casana P., Martinez F., Lorenzo J.I., et al. New mutations detected in patients with different types of von Willebrand disease. Thromb. Haemost. 82:1999;614.
214. Abuzenadah A.M., Gursel T., Ingerslev J., Nesbitt I.M., Peake I.R., Goodeve A.C. Mutational analysis of the von Willebrand factor gene in 27 families from Turkey with von Willebrand disease. Thromb. Haemost. 82:1999;283.
215. Allen S., Abuzenadah A.M., Hinks J., et al. A novel von Willebrand disease causing mutation (Arg273Trp) in von Willebrand factor propeptide that results in defective multimerisation and secretion. Blood. 96:2000;560-568.
216. Keeney S., Cumming A.M. The molecular biology of von Willebrand disease. Clin. Lab. Haematol. 23:2001;209-230.
217. Eikenboom J.C., Castaman G., Vos H.L., Bertina R.M., Rodeghiero F. Characterisation of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb. Haemost. 79:1998;709-717.
218. Casana P., Martinez F., Hay S., Espinos C., Aznar J.A. Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br. J. Haematol. 115:2001;692-700.
219. Dent J.A., Berkowitz S.D., Ware J., Kasper C.K., Ruggeri Z.M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc. Natl. Acad. Sci. 87:1990;6306-6310.
220. Jenkins P.V., Pasi K.J., Perkins S.J. Molecular modelling of ligand and mutation sites of the type A domains of human von Willebrand Factor and their relevance to von Willebrand's disease. Blood. 91:1998;2032-2044.
221. Meyer D., Fressinaud E., Gaucher C., et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand Disease: from the patient to the gene. Thromb. Haemost. 78:1997;451-456.
222. Ribba A.S., Hilbert L., Lavergne J.M., Fressinaud E., Mazurier C., Meyer D. Mutations at positions 513, 552, 611, and 695 in the A1 loop of von Willebrand factor induce a type 2A phenotype, usefulness of Botrocetin to distinguish type 2A and type 2M von Willebrand disease. Thromb. Haemost. 82:1999;510.
223. Lyons S.E., Bruck M.E., Bowie E.J., Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J. Biol. Chem. 267:1992;4424-4430.
224. Ginsburg D., Bowie E.J.W. Molecular genetics of von Willebrand disease. Blood. 79:1992;2507-2519.
225. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., Fujikawa K. Structure of von Willebrand Factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:2001;41059-41063.
226. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:2001;1662-1666.
227. Ribba A.S., Hilbert L., Lavergne J.M., et al. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: as study of 10 patients and mutated recombinant von Willebrand factor. Blood. 97:2001;952-959.
228. Gaucher C., Dieval J., Mazurier C. Characterisation of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood. 84:1994;1024-1030.
229. Holmberg L., Karpman D., Isaksson C., Kristofferson A.C., Lethagen S., Schneppenheim R. Ins405AsnPro mutation in the von Willebrand Factor propeptide in recessive type 2A(IIC) von Willebrand's disease. Thromb. Haemost. 79:1998;718-722.
230. Schneppenheim R., Thomas K.B., Krey S., et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum. Genet. 95:1995;681-686.
231. Zimmerman T.S., Dent J.A., Ruggeri Z.M., Nannini L.H. Subunit composition of plasma von Willebrand factor. J. Clin. Invest. 77:1986;947-951.
232. Schneppenheim R., Brassard J., Krey S., et al. Defective dimerisation of von Willebrand factor subunits due to Cys→Arg mutation in type IID von Willebrand disease. Proc. Natl. Acad. Sci. 93:1996;3581-3586.
233. Schneppenheim R., Budde U., Obser T., et al. Expression and characterisation of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood. 97:2001;2059-2066.
234. Enayat M.S., Guilliatt A.M., Surddhar G.K., et al. Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. Blood. 98:2001;674-680.
235. Katsumi A., Tuley E.A., Bodo I., Sadler J.E. Localization of disulphide bonds in the cystine knot domain of human von Willebrand factor. J. Biol. Chem. 275:2000;25585-25594.
236. Voorberg J., Fontin R., van Mourik J.A., Pannekoek H. Domains involved in mulimer assembly of von Willebrand factor (vWF): Multimerisation is independent of dimerisation. EMBO J. 9:1990;793-803.
237. De Groot P.G., Federici A.B., de Boer H.C., D'Alessio P., Mannucci P.M., Sixma J.J. Von Willebrand factor synthesised by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets. Proc. Natl. Acad. Sci. 86:1989;3793-3797.
238. Casana P., Martinez F., Haya S., Tavares A., Aznar J.A. New Mutations in exon 28 of the von Willebrand factor gene detected in patients with different types of von Willebrand's disease. Haematologica. 86:2001;414-416.
239. Ribba A.S., Christopher O., Derlon A., et al. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease. Blood. 83:1994;833-841.
240. Rendal E., Penas N., Larrabeiti B., et al. Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship. Ann. Hematol. 80:2001;354-360.
241. Hilbert L., Jenkins P.V., Gaucher C., et al. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb. Haemost. 84:2000;188-194.
242. Hillery C.A., Mancuso D.J., Sadler J.E., et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood. 91:1998;1572-1581.
243. Schneppenheim R., Federici A.B., Budde U., et al. von Willebrand disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A, R1205H) in 8 families. Thromb. Haemost. 82:2000;136-140.
244. Castaman G., Missiaglia E., Federici A.B., Schneppenheim R., Rodeghiro F. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2M Vicenza and the G3864A (R1205H) mutation. Thromb. Haemost. 84:2000;350-351.
245. Casonato A., Pontara E., Sartorello F., et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 99:2002;180-184.
246. Ribba A.S., Loisel I., Lavergne J.M., et al. Ser968Thr mutation within the A3 domain of von Willebrand factor in two related patients leads to a defective binding of vWF to collagen. Thromb. Haemost. 86:2001;848-854.
247. Fischer B.E., Thomas K.B., Schlokat U., Dorner F. Triplet structure of human von Willebrand factor. Biochem. J. 331:1998;483-488.
248. Rastegar-Lari G., Ajzenberg N., Ribba A.S., et al. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutation. Thromb. Haemost. 86:2001;1459-1465.
249. Ajzenberg N., Ribba A.S., Rastegar-Lari G., Meyer D., Baruch D. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood. 95:2000;3796-3803.
250. Lankhof H., Damas C., Schiphorst M.E., et al. Functional studies on platelet adhesion with recombinant von Willebrand Factor Type 2B mutants R543Q and R543W under conditions of flow. Blood. 89:1997;2766-2772.
251. Tuley E.A., Gaucher C., Jorieux S., Worrall N.K., Sadler J.E., Mazurier C. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc. Natl. Acad. Sci. 88:1991;6377-6381.
252. Jorieux S., Tuley E.A., Gaucher C., Mazurier C., Sadler J.E. The mutation Arg(53)-Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood. 79:1992;563-567.
253. Cacheris P.M., Nichols W.C., Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. J. Biol. Chem. 266:1991;13499-13502.
254. Kroner P.A., Friedman K.D., Fahs S.A., Scott J.P., Montgomery R.R. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J. Biol. Chem. 266:1991;19146-19149.
255. Jorieux S., Gaucher C., Goudemand J., Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerisation. Blood. 92:1998;4663-4670.
256. Zhang Z.P., Falk G., Blomback M., Egberg N., Anvret M. Identification of a new nonsense mutation in the von Willebrand factor gene in patients with von Willebrand disease type III. Hum. Mol. Genet. 1:1992;61-62.
257. Nesbitt I.M., Goodeve A.C., Guilliatt A.M., Makris M., Preston F.E., Peake I.R. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thromb. Haemost. 75:1996;959-964.
258. Allen S., Abuzenadah A.M., Blagg J.L., et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerisation and secretion of von Willebrand factor. Blood. 95:2000;2000-2007.
259. Jorieux S., Fressinaud E., Goudemand J., Gaucher C., Meyer D., Mazurier C. Conformational changes in the D′ domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood. 95:2000;3139-3145.
260. Nitu-Whalley I.C., Riddell A., Lee C.A., et al. Identification of type 2 von Willebrand Disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb. Haemost. 84:2000;998-1004.
261. Zhang Z.P., Falk G., Blomback M., Egberg N., Anvret M. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish type III patients. Hum. Mol. Genet. 96:1992;388-394.
262. Baronciani L., Cozzi G., Canciani M.T., et al. Molecular characterisation of a multiethnic group of 21 patients with type 3 von Willebrand Disease. Thromb. Haemost. 84:2000;536-540.
263. Miller J.L., Castella A. Platelet-type von Willebrand disease: characterization of a new bleeding disorder. Blood. 60:1982;790-794.
264. Miller J.L., Cunningham D., Lyle V.A., Finch C.N. Mutation in the gene encoding the α chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc. Natl. Acad. Sci. 88:1991;4761-4765.
265. Russell S.D., Roth G.J. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood. 81:1993;1787-1791.
266. Takahashi H., Murata M., Moriki T., et al. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood. 85:1995;727-733.
267. Kunishima S., Heaton D.C., Naoe T., et al. De novo mutation of the platelet glycoprotein Ib alpha gene in a patient with pseudo-von Willebrand disease. Blood. Coagul. Fibrinol. 8:1997;311-315.
268. 239→Val) reported in patients with platelet-type von Willebrand disease. Blood. 90:1997;698-705.
269. Tait A.S., Cranmer S.L., Jackson S.P., Dawes I.W., Chong B.H. Phenotype changes resulting in high affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease mutations. Blood. 98:2001;1812-1818.
270. 248 disulphide loop. J. Biol. Chem. 275:2000;27663-27670.
271. Federici A.B., Rand J.H., Bucciarelli P., et al. Acquired von Willebrand syndrome: data from an international registry. Thromb. Haemost. 84:2000;345-349.
272. Sanchez-Luceros A., Meschengieser S.S., Woods A.I., et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica. 87:2002;264-270.
273. Casonato A., Pontara E., Doria A., et al. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. Br. J. Haematol. 116:2002;899-904.
274. Veyradier A., Jenkins C.S.P., Fressinaud E., Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb. Haemost. 84:2000;175-182.
275. Michiels J.J., Budde U., Vander Planken M., van Vliet H.H.D.M., Schroyens W., Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Bailliere's Best Practice Clin. Haematol. 14:2001;401-436.
276. Kenny D., Jonsson O.G., Morateck P.A., Montgomery R.R. Naturally occurring mutations in Glycoprotein Ibα that result in defective ligand binding and synthesis of truncated protein. Blood. 92:1998;175-183.
277. Holmberg L., Karpman D., Nilsson I., Olofsson T. Bernard-Soulier syndrome Karlstad: Trp489→stop mutation resulting in truncated glycoprotein Ib alpha that contains part of the transmembrane domain. Br. J. Haematol. 98:1997;57-63.
278. Kenny D., Jonsson O.G., Morateck P.A., Montgomery R.R. Naturally occurring mutations in glycoprotein Ibα that result in defective ligand binding and synthesis of a truncated protein. Blood. 92:1998;175-183.
279. Afshar-Kharghan V., Lopez J.A. Bernard-Soulier syndrome caused by a dinucleotide deletion and reading frameshift in the region encoding the glycoprotein Ibα transmembrane domain. Blood. 90:1997;2634-2643.
280. Li C., Martin S.E., Roth G.J. The genetic defect in two well-studied cases of Bernard-Soulier syndrome: a point mutation in the fifth leucine-rich repeat of platelet glycoprotein Ib alpha. Blood. 86:1995;3805-3814.
281. Miller J.L., Lyle V.A., Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood. 79:1992;439-446.
282. Ware J., Russell S.R., Marchese P., et al. Point mutation in a leucine-rich repeat of platelet glycoprotein alpha resulting in the Bernard-Soulier syndrome. J. Clin. Invest. 92:1993;1213-1220.
283. de la Salle C., Baas M.J., Lanza F., et al. A three-base deletion removing a leucine residue in a leucine repeat of platelet glycoprotein Ib alpha associated with a variant of Bernard-Soulier syndrome. Br. J. Haematol. 89:1995;386-396.
284. Simsek S., Noris P., Lozano M., et al. Cys209Ser mutation in the platelet membrane glycoprotein I alpha gene is associated with Bernard-Soulier syndrome. Br. J. Haematol. 88:1994;839-844.
285. Ware J., Russell S.R., Vicente V., et al. Nonsense mutation in the glycoprotein Ibα coding sequence associated with Bernard-Soulier syndrome. Proc. Natl. Acad. Sci. 87:1990;2026-2030.
286. Kunishima S., Miura H., Fukutani H., et al. Bernard-Soulier syndrome Kagoshima: Ser 444→stop mutation of glycoprotein (GP) Ib alpha resulting in circulating truncated GP Ib alpha and surface expression of GP Ib beta and GP IX. Blood. 84:1994;3356-3362.
287. Kenny D., Morateck P.A., Gill J.C., Montgomery R.R. The critical interaction of glycoprotein Ibα with GP IX-a genetic cause of Bernard-Soulier syndrome. Blood. 93:1999;2968-2975.
288. Moran N., Morateck P.A., Deering A., et al. Surface expression of glycoprotein Ibα is dependent on glycoprotein Ibα: evidence from a novel mutation causing Bernard-Soulier syndrome. Blood. 96:2000;532-539.
289. Kunishima S., Lopez J.A., Kobayashi S., et al. Missense mutations of the glycoprotein (GP) Ibβ gene impairing the GP Ib α/β disulphide linkage in a family with giant platelet disorder. Blood. 89:1997;2404-2412.
290. Ludlow L.B., Schick B.P., Budarf M.L., et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibβ promoter resulting in the Bernard-Soulier syndrome. J. Biol. Chem. 271:1996;22076-22080.
291. Clemetson J.M., Kyrle P.A., Brenner B., Clemetson K.J. Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX. Blood. 84:1994;1124-1131.
292. Noris P., Simsek S., Stibbe J., von dem Borne A.E. A phenylalanine-55 to serine amino-acid substitution in the human glycoprotein IX leucine-rich repeat is associated with Bernard-Soulier syndrome. Br. J. Haematol. 97:1997;312-320.
293. Noda M., Fujimura K., Takafuta T., et al. A point mutation in glycoprotein IX coding sequence (Cys73(TGT) to Tyr(TAT) causes impaired surface expression of GP Ib/IX/V complex in two families with Bernard-Soulier syndrome. Thromb. Haemost. 76:1996;874-878.
294. Noda M., Fujimura K., Takafuta T., et al. Heterogeneous expression of glycoprotein Ib, IX and V in platelets from two patients with Bernard-Soulier syndrome caused by different genetic abnormalities. Thromb. Haemost. 74:1995;1411-1415.
295. Wright S.D., Michaelidis K., Johnson D.J., West N.C., Tuddenham E.G. Double heterozygosity for mutations in the platelet glycoprotein IX in three siblings with Bernard-Soulier syndrome. Blood. 81:1993;2339-2347.
296. Sae-Tung G., Dong J.F., Lopez J.A. Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-Soulier syndrome. Blood. 87:1996;1361-1367.
297. Lanza F., de La Salle C., Baas M., et al. A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GP Ib-V-IX complex. Br. J. Haematol. 118:2002;260-266.
298. 3 deficiency. Int. J. Haematol. 72:2000;448-454.
299. D'Andrea G., Colaizzo D., Vecchione G., Grandone E., Di Minno G., Margaglione M. Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb. Haemost. 87:2002;1034-1042.
300. 3. J. Biol. Chem. 271:1996;30544-30547.
301. Loftus J.C., O'Toole T.E., Plow E.F., Glass A., Frelinger A.L.F. Ginsberg MH.A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 249:1990;915-918.
302. D'Souza S., Ginsberg M., Burke T., lam S., Plow E. Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets. Science. 242:1988;91-93.
303. 3. J. Biol. Chem. 271:1996;2033-2039.
304. Charo I.F., Nannizzi L., Philips D.R., Hsu M.A., Scarborough R.M. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J. Biol. Chem. 266:1991;1415-1421.
305. Lanza F., Stierle A., Fournier D., et al. A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg-214Trp mutation. J. Clin. Invest. 89:1992;1995-2004.
306. 3 subunit. J. Biol. Chem. 271:1996;21978-21984.
307. D'Souza S.E., Ginsberg M.H., Burke T.A., Plow E.F. The ligand binding site of the platelet integrin receptor GP IIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. J. Biol. Chem. 265:1990;3440-3446.
308. Poncz M., Eisman R., Heidenreich R. Structure of the membrane glycoprotein IIb. J. Biol. Chem. 262:1987;8476-8482.
309. 3. J. Biol. Chem. 274:1999;4633-4639.
310. McDonald J.A. Integrins minireview series. J. Biol. Chem. 275:2000;21783.
311. 3 are clustered in the β-propeller model. J. Biol. Chem. 276:2001;44275-44283.
312. Plow E.F., Haas T.A., Zhang L., Loftus J., Smith J.W. Ligand binding to integrins. J. Biol. Chem. 275:2000;21785-21788.
313. Ambo H., Kamata T., Handa M., et al. Three novel β3 subunit missense mutations (H280P, C560F and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem. Biophys. Res. Commun. 251:1998;763-768.
314. 327 for β3 integrin subunit association. Blood. 90:1997;669-677.
315. 3 export to the platelet surface. Blood. 90:1997;3082-3088.
316. 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J. Biol. Chem. 267:1992;3789-3794.
317. 3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia. Thromb. Haemost. 80:1998;42-48.
318. 3) integrin receptor locked in a high affinity state and Glanzmann thrombasthenia-like phenotype. Blood. 98:2001;2432-2441.
319. Zucker M.B., Masiello N.C. Platelet aggregation caused by dithiothreitol. Thromb. Haemost. 51:1984;119-124.
320. 3) integrin complexes. Blood. 100:2002;2094-2101.
321. 3. Thromb. Haemost. 80:1998;735-742.
322. Gonzalez-Manchon C., Fernandez-Pinel M., Arias-Salgado E.G., et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the 674-687 disulphide bridge in GP IIb prevents surface exposure of GP IIb-IIIa complexes. Blood. 93:1999;866-875.
323. IIb subunit is associated with a variant of Glanzmann thrombasthenia. J. Clin. Invest. 102:1998;1183-1192.
324. Grimaldi C.M., Chen F., Wu C., Weiss H.J., Coller B.S., French D.L. Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GP IIb/IIIa. Blood. 91:1998;1562-1571.
325. 3. Blood. 95:2000;180-188.
326. Tao J., Arias-Salgado E.G., Gonzalez-Manchon C., et al. A 1063G→A mutation in exon 12 of glycoprotein (GP) IIb associated with a thrombasthenic phenotype: mutation analysis of [324E] GP IIb. Br. J. Haematol. 111:2000;965-973.
327. Wilcox D.A., Wautier J.L., Pidard D., Newman P.J. A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. J. Biol. Chem. 269:1994;4450-4457.
328. Poncz M., Rifat S., Coller B.S., et al. Glanzmann thrombasthenia secondary to a Gly273→Asp mutation adjacent to the first calcium binding domain of platelet glycoprotein IIb. J. Clin. Invest. 93:1994;172-179.
329. 3 subunit and defective
330. 3 complex. J. Clin. Invest. 200:1997;2393-2403.
331. Baker E.K., Tozer E.C., Pfaff M., Shattil S.J., Loftus J.C., Ginsberg M.H. A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro. Proc. Natl. Acad. Sci. 94:1997;1973-1978.
332. Malik U., Dutcher J.P., Oleksowicz L. Acquired Glanzmann's thrombasthenia associated with Hodgkins lymphoma. Cancer. 82:1998;1764-1768.
333. Moroi M., Jung S.M., Okuma M., Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J. Clin. Invest. 84:1989;1440-1445.
334. Moroi A., Yamamoto N., Moroi M., Akamatsu N., Fukutake K., Tanque K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding deficiency. Br. J. Haematol. 89:1995;124-130.
335. Nieuwenhius H.K., Akkerman J.W.N., Houdijk W.P.M., Sixma J.J. Human blood platelets showing no response to collagen fail to express glycoprotein Ia. Nature. 318:1985;470-472.
336. Nieuwenhuis H.K., Sakariassen K.S., Houdijk W.P.M., Nievelstein P.F.M., Sixma J.J. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood. 68:1986;692-695.
337. Kehrel B., Balleisen L., Kokott R., et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen induced aggregation and spontaneous loss of disorder. Blood. 71:1988;1074-1078.
338. Clemetson K.J., Clemetson J.M. Platelet collagen receptors. Thromb. Haemost. 86:2001;189-197.
339. Bussel J.B., Kunicki T.J., Michelson A.D. Platelets: new understanding of platelet glycoproteins and their role in disease. Haematology. 5:2000;222-240.
340. Deckmyn H., Chew S.L., Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia. A novel cause of acquired platelet dysfunction. Thromb. Haemost. 64:1990;74-79.
341. 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb. Haemost. 73:1995;521-528.
342. 2 gene coding sequence. Blood. 89:1997;1939-1943.
343. Kunicki T.J., Orchekowski R., Annis D., Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood. 82:1993;2693-2703.
344. 1 density. Blood. 92:1998;2382-2388.
345. Jacquelin B., Tarantino M.D., Kritzik M., et al. Allele-dependent transcriptional regulation of the human integrin α2 gene. Blood. 97:2001;1721-1726.
346. 1 density and von Willebrand factor. Blood. 96:2000;1433-1437.
347. 1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 93:1999;3578-3582.
348. Cattaneo M., Lecchi A., Randi A.M., McGregor J.L., Mannucci P.M. Identification of a new congenital defect of platelet function characterised by severe impairment of platelet responses to adenosine diphosphate. Blood. 80:1992;2787-2796.
349. Nurden P., Savi P., Heilmann E., et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J. Clin. Invest. 95:1995;1612-1622.
350. 1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb. Haemost. 81:1999;775-781.
351. 2 production and normal granule stores. Arterioscler. Thromb. Vasc. Biol. 20:2000;101-106.
352. 1 receptor leads to a mild bleeding disorder. Thromb. Haemost. 82:1999;20.
353. Oury C., Toth-Zsamboki E., Van Geet C., Nilius B., Vermylen J., Hoylaerts M.F. A dominant negative mutation in the platelet P2X1 ADP receptor causes severe bleeding disorder: important role of P2X1 in ADP induced platelet aggregation. Blood. 94:1999;618a.
354. Oury C., Toth-Zsamboki E., Thys C., Vermylen J., Hoylaerts M. ADP-induced activation of the extracellular regulated kinase/mitogen activated protein pathway via the ionotropic P2X1-knockout mice. Haematologica. 85:2000;89.
355. 2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. 94:1994;1662-1667.
356. 2 binding activity. Thromb. Haemost. 82:1999;1528-1531.
357. Hollenberg M.D., Compton S.J. Proteinase activated receptors. Pharmacol. Rev. 54:2002;203-217.
358. Brass L.F., Manning D.R., Cichowski K., Abrams C.S. Signaling through G proteins in platelets: to the integrins and beyond. Thromb. Haemost. 78:1997;581-589.
359. Lages B., Weiss H.J. Heterogeneous defects of platelets secretion and responses to weak agonists in patients with bleeding disorders. Br. J. Haematol. 68:1988;53-62.
360. Yang X., Sun L., Gabbeta J., Rao A.K. Platelet activation with combination of ionophore A23187 and a direct protein kinase C activator induces normal secretion in patients with impaired receptor mediated secretion and abnormal signal transduction. Thromb. Res. 88:1997;317-328.
361. Gabbeta J., Yang X., Kowalska M.A., Sun L., Dhanasekaran N., Rao K. Platelet signal transduction defect with Gα subunit dysfunction and diminished Gαq in a patient with abnormal platelet responses. Proc. Natl. Acad. Sci. 94:1997;8750-8755.
362. Lee S.B., Rao A.K., Lee K.H., Yang X., Bae Y.S., Rhee S.G. Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood. 88:1996;1684-1691.
363. Mao G.F., Vaidyula V.R., Kunapuli S.P., Rao A.K. Lineage-specific defect in gene expression in human platelet phospholipase C-β2 deficiency. Blood. 99:2002;905-911.
364. Gabbeta J., Yang X., Sun L., McLane M.A., Niewiaowski S., Rao A.K. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood. 87:1996;1368-1376.
365. Freson K., Hoylaerts M.F., Jaeken J., et al. Genetic variation of the extra-large stimulatory G protein α-subunit leads to Gs hyper function in platelets and is a risk factor for bleeding. Thromb. Haemost. 86:2001;733-738.
366. Reik W., Walter J. Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2:2001;21-32.
367. Sims P.J., Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb. Haemost. 86:2001;266-275.
368. Zwaal R.F.A., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 89:1997;1121-1132.
369. Zhou Q., Zhao J., Sout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. J. Biol. Chem. 272:1997;18240-18244.
370. Weiss H.J., Vicic W.J., Lages B.A., Rogers J. Isolated deficiency of platelet procoagulant activity. Am. J. Med. 67:1979;206-212.
371. Weiss H.J. Scott syndrome: a disorder of platelet coagulant activity. Semin. Haematol. 31:1994;312-319.
372. 2+-induced tyrosine phosphorylation and defective lipid scrambling in erythrocytes from a patient with Scott Syndrome: a study using an inhibitor for scramblase that mimics the defect in Scott syndrome. Blood. 91:1998;2133-2138.
373. Toti F., Satta N., Fressinaud E., Meyer D., Freyssinet J.M. Scott syndrome, characterised by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood. 87:1996;1409-1415.
374. Weiss H.J., Lages B. Platelet prothrombinase activity and intracellular calcium response in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency or impaired platelet coagulant activity - a comparison with Scott syndrome. Blood. 89:1997;1599-1611.
375. 2+-dependent transbilayermigration of membrane phospholipids. J. Clin. Invest. 99:1997;2232-2238.
376. Stormorken H., Holmsen H., Sund R., et al. Studies on the hemostatic defect in a complicated syndrome: an inverse Scott syndrome platelet abnormality? Thromb. Haemost. 74:1995;1244-1251.
377. Stormorken H., Sjaastad O., Langslet A., Sulg I., Egge K., Diderichsen J. A new syndrome: thrombocytopathia, muscle fatigue, asplenia, miosis, migraine, dyslexia and ichthyosis. Clin. Genet. 28:1985;367-374.
378. Fuse I. Disorders of platelet function. Crit. Rev. Oncol./Haematol. 22:1996;1-25.
379. Nieuwenhuis H.K., Akkerman J.W.N., Sixma J.J. Patients with prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood. 70:1987;620-623.
380. White J.G. Ultrastructural studies of the gray platelet syndrome. Am. J. Pathol. 95:1979;445-462.
381. Levy-Toledano S., Caen J.P., Breton-Gorius J., et al. Gray platelet syndrome: alpha granule deficiency. Its influence on platelet function. J. Lab. Clin. Med. 98:1981;831-848.
382. Breton-Gorius J., Vainchenker W., Nurden A., Levy-Toledano S., Caen J. Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultra structural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am. J. Pathol. 102:1981;10-19.
383. Rosa J.P., George J.N., Bainton D.F., Nurdeeeeen A.T., Caen J.P., McEver R.P. Gray platelet syndrome. Demonstration of alpha granule membranes that can fuse with the cell surface. J. Clin. Invest. 80:1987;1138-1146.
384. Reed G.L., Fitzgerald M.L., Polgar J. Molecular mechanisms of platelet exocytosis: insights into the 'secrete' life of thrombocytes. Blood. 96:2000;3334-3342.
385. Drouin A., Favier R., Masse J.M., et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood. 98:2001;1382-1391.
386. Falik-Zaccai T.C., Anikster Y., Rivera C.E., et al. A new genetic isolate of gray platelet syndrome(GPS): clinical, cellular and hematologic characteristics. Mol. Genet. Metab. 74:2001;303-313.
387. Hayward C.P.M., Cramer E.M., Kane W.H., et al. Studies of a second family with Quebec platelet disorder: evidence that the degradation of the α-granule and its soluble contents are not secondary to a defect in targeting proteins to α-granules. Blood. 89:1997;1243-1253.
388. Kahr W.H., Zheng S., Sheth P.M., et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood. 98:2001;257-265.
389. Hayward C.P.M., Welch B., Bouchard M., Zheng S., Rivard G.E. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br. J. Haematol. 97:1997;497-503.
390. Krisp A., Hoffman R., Happle R., Konig A., Freyschmidt-Paul P. Hermansky-Pudlak syndrome. Eur. J. Dermatol. 11:2001;372-373.
391. Suzuki T., Li W., Zhang Q., et al. Hermansky-Pudlak syndrome is caused by mutations in HPS4, the human homolog of the mouse light-ear gene. Nat. Genet. 30:2002;321-324.
392. Huizing M., Anikster Y., Gahl W.A. Hermansky-Pudlak syndrome and Chediak-Higashi syndrome: disorders of vesicle formation and trafficking. Thromb. Haemost. 86:2001;233-245.
393. Tchernev V.T., Mansfield T.A., Giot L., et al. The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins. Mol. Med. 8:2002;56-64.
394. Oda A., Ochs H.D. Wiskott-Aldrich syndrome protein and platelets. Immunol. Rev. 178:2000;111-117.
395. Remold-O'Donnell E., Rosen F.S., Kenney D.M. Defects in Wiskott-Aldrich syndrome blood cells. Blood. 87:1996;2621-2631.
396. Nieswandt B., Bergmeier W., Eckly A., et al. Evidence for cross-talk between glycoprotein VI and Gi coupled receptors during collagen-induced platelet aggregation. Blood. 97:2001;3829-3835.
397. Weiss E.J., Bray P.F., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl. J. Med. 334:1996;1090-1094.